What Fueled The Previous Growth In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
The cell and gene therapy contract development and manufacturing organization (cdmo) market has seen considerable growth due to a variety of factors.
• The cell and gene therapy contract development and manufacturing organization (CDMO) market has seen exponential growth in recent years. It will increase from $5.41 billion in 2024 to $6.94 billion in 2025, reflecting a compound annual growth rate (CAGR) of 28.2%.
The historical growth is attributed to technological advancements, favorable regulatory frameworks, greater investment in the sector, the high prevalence of genetic disorders, and a rising number of strategic partnerships.
What Is The Expected Growth In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Size Evolve over the Forecast Period?
The cell and gene therapy contract development and manufacturing organization (cdmo) market is expected to maintain its strong growth trajectory in upcoming years.
• The cell and gene therapy contract development and manufacturing organization (CDMO) market is forecast to grow to $18.54 billion by 2029 at a CAGR of 27.8%.
This growth is driven by expanded therapeutic applications, regulatory evolution, technological innovations, and global collaboration. Trends include increased demand for personalized therapies, automation and digitalization, manufacturing capacity expansion, novel delivery systems, and sustainability.
What Main Forces Are Fueling Expansion In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
The increasing prevalence of cancer is set to drive the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market. The rise in cancer cases is linked to aging populations, lifestyle changes, and better detection methods. CDMOs play a role in developing targeted therapies for cancer that improve treatment efficacy. For instance, in October 2022, Macmillan Cancer Support projected that the number of people living with cancer in the UK would rise from 3 million in 2022 to 5.3 million by 2040. The increasing cancer burden is driving the CDMO market.
What Are The Primary Segments In The Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented –
1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy
2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4
3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications
Subsegments:
1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy
2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy
3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy
Pre-Book The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Industry?
Companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are expanding their portfolios with technologies like PluriMatrix to boost scalability and manufacturing efficiency. PluriMatrix is a proprietary technology for large-scale cell-based product production. For instance, in January 2024, Israel-based Pluri introduced PluriCDMO, a new division offering cell therapy manufacturing services. The division includes a GMP-certified facility and provides end-to-end services, including preclinical to commercial-scale production, process validation, and regulatory support.
Who Are the Key Players In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are:
• Pfizer Inc.
• Merck & Co. Inc.
• Thermo Fisher Scientific Inc.
• Novartis AG
• FUJIFILM Diosynth Biotechnologies
• AGC Biologics
• Ajinomoto Co Inc.
• Lonza Group
• Catalent Inc.
• Charles River Laboratories International Inc.
• Sartorius Stedim Biotech
• Samsung Biologics Co Ltd.
• WuXi Biologics
• Recipharm AB
• Almac Group Ltd.
• KBI Biopharma
• Rentschler Biopharma
• Bio Elpida
• Oxford BioMedica Plc
• Avid Bioservices Inc.
• Cell and Gene Therapy Catapult
• VGXI Inc.
• Genezen Laboratories Inc.
• Pluri Inc.
• OmniaBio Inc.
What Is The Most Dominant Region In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
